News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XYMOGEN Achieves Record Revenues And Earnings Along With A Strong Start To 2014



3/18/2014 9:34:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ORLANDO, Fla., March 18, 2014 /PRNewswire/ -- Orlando-based health sciences company XYMOGEN has announced record revenues and earnings [EBITDA] for fiscal year 2013. The announcement was made to employees and customers at the 2014 XYMOGEN XPERIENCE event in January.

XYMOGEN has revealed $59 million in revenue and $3.7 million in earningsa 27 percent growth from the company's numbers of the previous year. Senior Vice President Mike Mahoney, attributes XYMOGEN's continued success in a sluggish economy to the company's "People First" culture, which places emphasis on the needs of customers and employees over profits and revenue.

"It's relationships. It's people first," said Mahoney. "We have always taken the time to listen to our customers, which has been a huge factor in XYMOGEN's growth over the last few yearsit gives us the input we need to release better quality products in high demand."

The company presented 2013's success at the second annual XYMOGEN XPERIENCE in January. The exclusive event drew more than 200 doctors, pharmacists and other health care practitioners from across the United States, Canada and Puerto Rico. Guests were treated to a tour of XYMOGEN's 136,000-square-foot manufacturing facility and headquarters, which opened in May-2012. The company attributes the event to its record shattering revenue and earnings for January 2014$6.3 million and $647,000, respectively.

"The majority of this January's growth may be attributed to the success of our annual XYMOGEN XPERIENCE," said Mike Mahoney, XYMOGEN's Senior Vice-President. "This year's event was even better than the 2013 XPERIENCE and was one of the most successful and celebrated events in company history."

Mahoney believes that the company's decision to focus on internal organization and infrastructure will lead it towards and even more successful 2014.

"With talented and experienced leadership in place in all divisions, XYMOGEN is well positioned to fully support a series of initiatives projected to increase revenues 53% to $90 Million for 2014."

About XYMOGEN
XYMOGEN, a family-owned, health sciences company with headquarters in Orlando, Fla., has been providing high-quality dietary supplements to licensed health care practitioners for more than a quarter century.

The nutraceutical company has introduced numerous innovations to the functional medicine community; its Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties.

XYMOGEN's strength as a company was reinforced in 2007, 2008, 2010, 2011, 2012 and 2013 when it was recognized by Inc. Magazine as one of the 5,000 fastest-growing, best-run, most innovative and most inspiring private companies in America.

The company's 136,000-square-foot manufacturing facility is GMP (good manufacturing practices) and GMP for Sport Athletic Banned Substances Program registered by NSF International.

More information is available at www.xymogen.com

Please email pr@xymogen.com for comments or inquiries.

Distributed by Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Suite 215
Winter Park, Florida 32789
407-702-6632
www.sarabradypr.com

For information, contact:
Sara R. Brady
407-702-6632

SOURCE XYMOGEN



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
XYMOGEN
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES